Supplementary Fig. 4. Changes from 12-month values in key clinical parameters for the different regimens during the 24 months of the study. Values are presented as mean±standard error. Regimens used after 12 months: (A) glycosylated hemoglobin (HbA1c), (B) body weight, (C) body mass index (BMI), (D) estimated glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration equation (eGFR-CKD-EPI), (E) alanine transaminase (ALT), and (F) total cholesterol. MTF+empa, metformin with empagliflozin; MTF+sita, metformin with sitagliptin; Triple, continuing metformin, sitagliptin, and empagliflozin. *P<0.05 vs. the extent of changes between the groups (analysis of variance [ANOVA] and post hoc Duncan test).